Cyclerion Therapeutics, Inc. (CYCN)

3.0500 +0.0800 (+2.69%) As of 04:00PM EDT. Market open.

Cyclerion Therapeutics, Inc.

245 First Street, Riverview II
18th Floor
Cambridge, MA 02142
United States
857 327 8778
https://www.cyclerion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Regina Graul Ph.D.	President	N/A	N/A	N/A
Ms. Rhonda M. Chicko	Chief Financial Officer	N/A	N/A	1967
Dr. Todd Milne Ph.D.	Senior Vice President of External Innovation	N/A	N/A	N/A
Ms. Jessica Rennekamp	Associate Director of Corporate Communications	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cyclerion Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.